Science News
from research organizations

Ovarian cancer researchers find biomarker linked to prognosis in aggressive disease type

Date:
March 7, 2017
Source:
University Health Network
Summary:
Ovarian cancer researchers have identified a protein biomarker expressed on the surface of tumor cells in high-grade serous ovarian cancer, the most common and lethal subtype of the disease.
Share:
FULL STORY

Ovarian cancer researchers have identified a protein biomarker expressed on the surface of tumour cells in high-grade serous ovarian cancer, the most common and lethal subtype of the disease.

The findings, featured on the cover of the March 7 issue of Cell Reports, show that patients with high levels of the biomarker, CD151, have a poor prognosis, says lead author Mauricio Medrano, a molecular biologist and research associate at Princess Margaret Cancer Centre, University Health Network.

"Ovarian cancer is many diseases," says Dr. Medrano. "By identifying CD151 and its underlying role in cancer cell survival, we hope to develop a therapy to target it. As a marker for poor prognosis, with further research, there is the potential to develop a clinical screening tool to help personalize cancer treatment for patients."

The research was led by principal investigator Dr. Robert Rottapel, senior scientist and Professor, Departments of Medical Biophysics and Immunology, University of Toronto.?

In lab experiments, the research team used cell lines derived from 40 patient tumour samples to identify that CD151 contributes to the survival of cells of high-grade serous ovarian cancer origin. The team further analysed tissue samples from a cohort of approximately 1,000 patients to establish the correlation of high levels of CD151 to poor prognosis.

"For the scientific community," says Dr. Medrano, "our study provides a lot of new information about other possible targets, not only CD151, that could be important and can provide new ideas for how to target ovarian cancer."


Story Source:

Materials provided by University Health Network. Note: Content may be edited for style and length.


Journal Reference:

  1. Mauricio Medrano, Laudine Communal, Kevin R. Brown, Marcin Iwanicki, Josee Normand, Joshua Paterson, Fabrice Sircoulomb, Paul Krzyzanowski, Marian Novak, Sasha A. Doodnauth, Fernando Suarez Saiz, Jane Cullis, Rima Al-awar, Benjamin G. Neel, John McPherson, Ronny Drapkin, Laurie Ailles, Anne-Marie Mes-Massons, Robert Rottapel. Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer. Cell Reports, 2017; 18 (10): 2343 DOI: 10.1016/j.celrep.2017.02.028

Cite This Page:

University Health Network. "Ovarian cancer researchers find biomarker linked to prognosis in aggressive disease type." ScienceDaily. ScienceDaily, 7 March 2017. <www.sciencedaily.com/releases/2017/03/170307130810.htm>.
University Health Network. (2017, March 7). Ovarian cancer researchers find biomarker linked to prognosis in aggressive disease type. ScienceDaily. Retrieved May 27, 2017 from www.sciencedaily.com/releases/2017/03/170307130810.htm
University Health Network. "Ovarian cancer researchers find biomarker linked to prognosis in aggressive disease type." ScienceDaily. www.sciencedaily.com/releases/2017/03/170307130810.htm (accessed May 27, 2017).

RELATED STORIES